Interventions of Interest:

  • Tezepelumab (Amgen, AstraZeneca)

ICER’s Evidence Report Findings:

Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic therapies; tezepelumab would achieve common thresholds for cost-effectiveness if priced between $9,000 – $12,100 per year.

At the November 19 virtual meeting, ICER’s independent appraisal committee will review the evidence, hear further testimony from stakeholders, and deliberate over tezepelumab’s comparative clinical effectiveness, other potential benefits, and long-term value for money

For more information, please contact Catherine Koola, Associate Director of Patient Engagement, at

View the Key Stakeholder List

David Rind, MD, ICER’s Chief Medical Officer stated:

“ICER previously reviewed biologic therapies for moderate-to-severe asthma, and none of these were effective in patients with allergic nor eosinophilic asthma. Tezepelumab has a new mechanism of action and does reduce exacerbations even in patients without eosinophilia who really have not had good options for treatment until now. In other asthma patients for whom biologics are available, tezepelumab is not clearly superior to those options, and it appears to be less effective in getting patients off oral steroids than dupilumab. Additionally, there remains a large unmet need for therapies that substantially improve daily quality of life in patients with severe asthma.”